Di Cocco B, Calabretta F, Alghisi F, Salesi N, Bossone G
Divisione di Oncologia Medica, Azienda Ospedaliera S.Andrea, Roma, Italy.
Minerva Ginecol. 2003 Aug;55(4):327-32.
Many circulating markers are already in clinical practice and in experimental use for the diagnosis, therapeutic monitoring, and in the follow-up of ovarian cancer. The cancer antigen-125 (CA-125) has shown to be useful in epithelial ovarian cancer, but its specificity is too low for the test to be used as a primary screening technique in early stage and particularly in premenopausal women. In the last few years, several studies have focused on using the serial measurement of complementary serum markers to improve the positive predictive value and diagnostic accuracy. The main problem is that the different cellular lines express these markers in a very variable way.
许多循环标志物已在临床实践中以及用于卵巢癌的诊断、治疗监测和随访的实验中使用。癌抗原125(CA-125)已被证明在上皮性卵巢癌中有用,但对于早期尤其是绝经前女性,其特异性过低,无法用作主要筛查技术。在过去几年中,多项研究聚焦于使用补充血清标志物的系列测量来提高阳性预测值和诊断准确性。主要问题是不同细胞系以非常可变的方式表达这些标志物。